01513 LIVZON PHARMA
- 29.350
- -0.250-0.84%
LIVZON PHARMA News
Livzon Pharmaceutical Group Cancels Share Options
Livzon Pharmaceutical Group (HKG:1513, SHE:000513) reported the cancelation of share options consistent with the shares offered in the second exercise period under the first grant and offered in the f
LIVZON PHARMA To Go Ex-Dividend On July 8th, 2024 With 1.48867 HKD Dividend Per Share
May 14th - $LIVZON PHARMA(01513.HK)$ is trading ex-dividend on July 8th, 2024. Shareholders of record on July 9th, 2024 will receive 1.48867 HKD dividend per share on August 5th, 2024. The ex-divi
Livzon Pharmaceutical Declares Final Dividend for 2023
Livzon Pharmaceutical Group (HKG:1513) declared a final dividend of 1.35 yuan per share for the year ended Dec. 31, 2023, according to a Monday filing on the Hong Kong bourse. The record date for the
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Livzon Pharmaceuticals (01513.HK) will pay a final dividend of $13.5 for every 10 shares of 2023 on August 5
Livzon Pharmaceuticals (01513.HK) announced that it will pay a final 2023 dividend of 13.5 yuan for every 10 shares on August 5, 2024.
Lizhu Pharmaceutical (01513) intends to provide joint and several liability guarantees for the credit financing applied for by Lijian Insurance from the Bank of Communications
Zhitong Finance App News, Lizhu Pharmaceutical (01513) issued an announcement. In order to meet the business needs of the company's holding subsidiary Lijian (Guangdong) Animal Health Co., Ltd. (hereinafter referred to as “Lijian Animal Insurance”), the company held the 16th meeting of the board of directors on May 13, 2024 to review and pass the “Proposal on the Company Providing Financing Guarantee for the Holding Subsidiary Lijian Life Insurance”, agreeing that the company can apply for credit financing of up to RMB 234.5 billion in full or equivalent foreign currency for Lijian Dongbao Joint and several liability guarantees.
Livzon Pharmaceuticals (01513) plans to cancel 6283.75 million stock options
According to Zhitong Finance App News, Lizhu Pharmaceutical (01513) announced that since the company's 2022 stock options incentive plan granted a second stock option exercise period for the first time (total of 5.283,500 options) and the first exercise period (total of 10.0 million options), corresponding to poor company-level performance, current options cannot be exercised. The board of directors of the company agreed to cancel a total of 6.28375 million of the above stock options.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
The guarantee balance of Lizhu Pharmaceutical (01513)'s holding subsidiary as of the end of April was $2.72 billion
Livzon Pharmaceuticals (01513) issued an announcement. In April 2024, Livzon Pharmaceutical Group Co., Ltd. and Bank of Communications...
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Livzon Pharmaceuticals (01513.HK): Repurchase a total of 2.778,800 H shares as of April 30
On May 6, GLONGHUI Pharmaceutical (01513.HK) announced that as of April 30, 2024, the company had repurchased a total of 2,778,800 shares of the company's H shares, accounting for 0.30% of the company's total share capital. The highest purchase price was HK$26.15 per share, the lowest price was HK$23.05 per share, and the total amount of capital used was HK$68.1574 million (excluding transaction fees). The above repurchase complies with the company's general authorization to repurchase H shares. As of April 30, 2024, the company has repurchased a total of 215.26 A-shares of the company through centralized bidding transactions
麗珠醫藥：2023年報
Pearl Group (000513): Steady performance, optimistic about long-term innovation and implementation
Maintain an “Overweight” rating. 2024Q1 revenue of 3.243 billion yuan (-5.0%), net profit attributable to mother of 608 million yuan (+4.5%), net profit after deducting non-attributable net profit of 590 million yuan (+3.6%), gross profit margin
Express News | Nanjing Jianyou and Livingzhu Group collaborated to export injectable cetrorelix acetate to the US for the first time
Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of mar
Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of market demand, and overall revenue and profit were in line with expectations; 2) they were optimistic about the accelerated implementation of high-end formulations and biopharmaceutical pipelines, and incremental products contributed to a peak sales of 6.5 billion yuan. (Mainichi Keizai Shimbun)
Pearl Group (000513): Excellent performance in the field of promotion and diagnostic reagents, and steady overall profit
Key investment events: The company announced its results for the first quarter of 2024. In 24Q1, the company achieved revenue of 3.243 billion yuan (-4.99%, same as below) and net profit to mother of 608 million yuan (+4.45%).
Express News | Livou Group: The company obtained approval from the US FDA for injectable cetrorelix acetate
Livzon Pharmaceuticals (01513.HK): Cetrorelix acetate for injection was approved by the US FDA
On April 26, GLONGHUI Pharmaceutical (01513.HK) issued an announcement. Recently, Lizhu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an ANDA approval notice (ANDA number: 214540) issued by the US Food and Drug Administration (hereinafter referred to as the “US FDA”) to approve the marketing and sale of injectable cetrorelix acetate developed by the company in the US.
April 25 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$61.109 million
According to documents disclosed by the Hong Kong Stock Exchange on April 26, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 25, involving an amount of HK$61.1091 million. The repurchase price per share ranged from HK$102.3 to HK$100.1. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 5.714 million shares, accounting for 0.299% of the number of shares issued when the ordinary resolution was passed. ② $
Pearl Pharmaceuticals (01513) spent HK$436,300 to buy back 16,700 shares on April 25
According to the Zhitong Finance App, Lizhu Pharmaceutical (01513) announced that on April 25, 2024, the company spent HK$436,300 to repurchase 16,700 shares at a repurchase price of HK$26-26.15 per share.
Analysis
Price Target
No Data
